Transgender individuals represent the fastest growing minority in the United States and are disproportionately affected by HIV. Hormone therapy is the most common treatment for gender dysphoria in transgender individuals. As HIV is an independent risk factor for coronary artery disease, it is critical to further research the influence masculinising and feminising hormone therapies have on cardiovascular disease. There is a clinical need for evidence-based guidelines for cardiologists to follow to effectively care for and treat transgender patients. For this to be done, the interplay between HIV, hormone therapy, and cardiovascular disease must be better understood through collaboration between researchers and clinicians to achieve maximum benefit from recent advancements.
Deutsch M. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people. San Francisco: Center of Excellence for Transgender Health, Department of Family and Community Medicine, University of California; 2016.
Mayer KH, Grinsztejn B, El-Sadr WM. Transgender people and HIV prevention: what we know and what we need to know, a call to action. J Acquir Immune Defic Syndr. 2016;72:207–9. CrossRef
Morselli E, Santos RS, Criollo A, et al. The effects of oestrogens and their receptors on cardiometabolic health. Nat Rev Endocrinol. 2017;13:352–64. CrossRef
Herrmann JL, Abarbanell AM, Weil BR, et al. Gender dimorphisms in progenitor and stem cell function in cardiovascular disease. J Cardiovasc Transl Res. 2010;3:103–13. CrossRef
Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310:1353–68. CrossRef
Streed CG Jr., Harfouch O, Marvel F, et al. Cardiovascular disease among transgender adults receiving hormone therapy: a narrative review. Ann Intern Med. 2017;167:256–67. CrossRef
Xu L, Freeman G, Cowling BJ, et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108. CrossRef
Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, et al. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2017;102:3914–23. CrossRef
Havlir DV, Currier JS. CROI 2016: complications of HIV infection and antiretroviral therapy. Top Antivir Med. 2016;24:38–46. PubMed
Vachiat A, McCutcheon K, Tsabedze N, et al. HIV and ischemic heart disease. J Am Coll Cardiol. 2017;69:73–82. CrossRef
Petoumenos K, Worm SW. HIV infection, aging and cardiovascular disease: epidemiology and prevention. Sex Health. 2011;8:465–73. CrossRef
Demir OM, Candilio L, Fuster D, et al. Cardiovascular disease burden among human immunodeficiency virus-infected individuals. Int J Cardiol. 2018;265:195–203. CrossRef
Gilbert JM, Fitch KV, Grinspoon SK. HIV-related cardiovascular disease, statins, and the REPRIEVE trial. Top Antivir Med. 2015;23:146–9. PubMed
Aberg JA, Sponseller CA, Ward DJ, et al. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV. 2017;4:e284–e94. CrossRef
Van Horn L, Carson JA, Appel LJ, et al. Recommended dietary pattern to achieve adherence to the American Heart Association/American College of Cardiology (AHA/ACC) guidelines: a scientific statement from the American Heart Association. Circulation. 2016;134:e505–e29. PubMed
- Gender, hormone therapy, and HIV: what should cardiologists know?
C. A. Martinez
R. R. Rikhi
- Bohn Stafleu van Loghum
Neu im Fachgebiet Kardiologie
e.Med Kampagnen-Visual, Mail Icon II